Differences in effectiveness and costs between treatments, per patient in the first year of treatment.
收藏NIAID Data Ecosystem2026-03-10 收录
数据链接：
官方服务：
资源简介：
The ICERs show that we pay €278,099 per QALY if we use aflibercept instead of bevacizumab and that ranibizumab is dominated by bevacizumab, meaning it is costlier, but does not yield health benefit.
创建时间：
2018-05-18
